ライフサイエンスコーパス: angiotensin-converting enzyme inhibitor

1 and without pretreatment with enalapril, an angiotensin converting enzyme inhibitor.

2 d were more often on diuretics, digoxin, and angiotensin converting enzyme inhibitors.

3 roteinuric angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.

4 system with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors.

5 ence to angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.

6 red thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors.

7 ives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.

8 , 378 (9.2%) were taking azathioprine and an angiotensin-converting enzyme inhibitor, 171 (12.9%) wer

9 et, 53% versus 66%; statins, 40% versus 52%; angiotensin-converting enzyme inhibitors, 20% versus 29%

10 [CI]: 49%-64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 2

11 We then imaged the effects of angiotensin-converting enzyme inhibitor (5 mg/kg enalapr

12 The occurrence of the casein-derived angiotensin converting enzyme-inhibitor (ACE-I) peptides

13 hypertensive medications included diuretics, angiotensin-converting enzyme inhibitors (ACE), and beta

14 lled trial planned to evaluate the impact of angiotensin-converting enzyme inhibitors (ACE-i) on the

15 al of the study was to assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and an

16 geting the renin-angiotensin system, such as angiotensin-converting enzyme inhibitors (ACE-Is) and an

17 appropriate initiation of beta blockers and angiotensin-converting-enzyme inhibitors (ACE-Is) or ang

18 There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angio

19 The angiotensin-converting enzyme inhibitor (ACEi) enalapril

20 and an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) has demon

21 conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiot

22 ation Trial (BENEDICT), all of whom received angiotensin-converting enzyme inhibitor (ACEI) therapy a

23 remental cost-effectiveness ratios (ICER) of angiotensin-converting enzyme inhibitor (ACEI), beta-blo

24 ective was to assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotens

25 ications to medical therapy, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotens

26 kground drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiot

27 The association between angiotensin-converting enzyme inhibitors (ACEI) and angi

28 Angiotensin-converting enzyme inhibitors (ACEi) for reni

29 vestigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angio

30 round clinician-directed therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angio

31 Angiotensin-converting enzyme inhibitors (ACEI) or angio

32 e first mechanistic evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angio

33 Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angio

34 We focused on angiotensin-converting enzyme inhibitors (ACEI), angiote

35 re with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiote

36 eatment doses of beta-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEI)/angioten

37 al trials of antihypertensive therapy (ARBs, angiotensin-converting-enzyme inhibitors [ACEi], beta bl

38 CI], -1.46 to -0.02; P = 0.01), specifically angiotensin-converting enzyme inhibitors (ACEIs) (beta =

39 Reduced potassium excretion caused by angiotensin-converting enzyme inhibitors (ACEis) and ang

40 The role of angiotensin-converting enzyme inhibitors (ACEIs) and ang

41 schemic heart disease, the pattern of use of angiotensin-converting enzyme inhibitors (ACEIs) in coro

42 Angiotensin-converting enzyme inhibitors (ACEIs) may ret

43 Angiotensin-converting enzyme inhibitors (ACEIs) or angi

44 hough several studies have shown that use of angiotensin-converting enzyme inhibitors (ACEIs) potenti

45 ion, that thiazide diuretics are superior to angiotensin-converting enzyme inhibitors (ACEIs), calciu

46 rm use of calcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respec

47 promulgated as an acceptable alternative to angiotensin-converting enzyme inhibitors (ACEIs).

48 It has been hypothesized that angiotensin-converting enzyme inhibitors (ACEIs)/angiote

49 dication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angi

50 ondition for which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiot

51 ics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardi

52 .50; 95% confidence interval, 0.48-0.52), or angiotensin-converting enzyme inhibitors (adjusted odds

53 but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1

54 Angiotensin-converting enzyme inhibitor also significant

55 Pairwise matching (1:1) of the angiotensin-converting enzyme inhibitor and angiotensin

56 2009 and 2010 in appropriate prescription of angiotensin-converting enzyme inhibitor and beta-blocker

57 ere -4.38 mm Hg (95% CI, -7.27 to -2.16) for angiotensin-converting enzyme inhibitors and -3.07 mm Hg

58 100 person-years for the patients receiving angiotensin-converting enzyme inhibitors and 2.87 per 10

59 orrhagic shock, 4) shocked mice treated with angiotensin-converting enzyme inhibitors and a single bo

60 prescribed drugs in the same year, including angiotensin-converting enzyme inhibitors and angiotensin

61 view that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin

62 This study aimed to compare the effect of angiotensin-converting enzyme inhibitors and angiotensin

63 e for CKD treatment benefit is strongest for angiotensin-converting enzyme inhibitors and angiotensin

64 ssessed for each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin

65 On admission, medical therapy, including angiotensin-converting enzyme inhibitors and angiotensin

66 Uptitration of angiotensin-converting enzyme inhibitors and beta blocke

67 Angiotensin-converting enzyme inhibitors and beta-blocke

68 ic, but not asymptomatic, heart failure with angiotensin-converting enzyme inhibitors and beta-blocke

69 -receptor blockers and statins, moderate for angiotensin-converting enzyme inhibitors and beta-blocke

70 Angiotensin-converting enzyme inhibitors and beta-blocke

71 We hypothesized that angiotensin-converting enzyme inhibitors and beta-blocke

72 ons known to be unsafe in pregnancy, such as angiotensin-converting enzyme inhibitors and statins, sh

73 de or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferio

74 Current standard therapy with angiotensin-converting enzyme inhibitors and/or angioten

75 rgic receptor blockers (beta-blockers), ACE (angiotensin-converting enzyme) inhibitors and ANG (angio

76 n, renal function, medication (beta-blocker, angiotensin converting enzyme inhibitor, and angiotensin

77 antiplatelet, antithrombotic, beta blocker, angiotensin-converting enzyme inhibitor, and statin agen

78 itration of beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensi

79 he use of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensi

80 Concomitant therapy with ARBs, angiotensin-converting enzyme inhibitors, and antiarrhyt

81 upporting the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowe

82 r disease medicines (aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins) i

83 0.8 [95% confidence interval, 0.64-0.98] for angiotensin-converting enzyme inhibitors; and relative r

84 to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin rec

85 scharge included the following: medications (angiotensin-converting enzyme inhibitors, angiotensin II

86 Angiotensin-converting enzyme inhibitors, angiotensin re

87 atio [UPCR] 500-5000 mg/g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin re

88 zine for 48 hours, and rapid up-titration of angiotensin-converting enzyme inhibitors, angiotensin re

89 classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin re

90 g or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-re

91 The medication classes examined were angiotensin-converting enzyme inhibitors, angiotensin-re

92 No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-re

93 ential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-re

94 f amlodipine 5 mg/day, a standard dose of an angiotensin converting enzyme inhibitor/angiotensin rece

95 Pivotal trials of beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin rec

96 nary intervention, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II r

97 to receive treatment with a beta-blocker, an angiotensin-converting enzyme inhibitor/angiotensin II r

98 nts' baseline characteristics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II r

99 s a combination of statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece

100 antiplatelet drug, statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece

101 B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin rece

102 and statins but were less likely to receive angiotensin-converting enzyme inhibitor/angiotensin rece

103 thin 24 hours, (2) aspirin at discharge, (3) angiotensin-converting enzyme inhibitor/angiotensin rece

104 Angiotensin-converting enzyme inhibitor/angiotensin rece

105 l/L increase, P<0.001; CI: 0.31-0.85), using angiotensin-converting enzyme inhibitor/angiotensin rece

106 Medications including statin, fibrate, angiotensin-converting enzyme inhibitor/angiotensin rece

107 Statin use was reported in only 30.5+/-2.5%, angiotensin-converting enzyme inhibitor/angiotensin rece

108 no statistically significant improvements in angiotensin-converting enzyme inhibitor/angiotensin rece

109 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin rece

110 idence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin rece

111 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin rece

112 current smoking, chronic kidney disease, and angiotensin-converting enzyme inhibitors/angiotensin II

113 current smoking, chronic kidney disease, and angiotensin-converting enzyme inhibitors/angiotensin II

114 e of and patient adherence to beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

115 vention with a combination of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

116 f 85 017 individuals, 55%, 76%, and 61% used angiotensin-converting enzyme inhibitors/angiotensin rec

117 ethnicity, but women were less likely to use angiotensin-converting enzyme inhibitors/angiotensin rec

118 Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin rec

119 escription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin rec

120 Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin rec

121 .11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin rec

122 Successive eras had greater usage of angiotensin-converting enzyme inhibitors/angiotensin rec

123 ational level, history of eczema, the use of angiotensin-converting enzyme inhibitors/angiotensin rec

124 In multivariable analyses, use of angiotensin-converting enzyme inhibitors/angiotensin rec

125 D not taking statins, 5.4 million not taking angiotensin-converting enzyme inhibitors/angiotensin rec

126 Utilization of statins, beta-blockers, and angiotensin-converting enzyme inhibitors/angiotensin rec

127 al therapy including statins, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

128 and 0.86 (0.74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

129 ficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin rec

130 , and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

131 es were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin rec

132 versus 57% in rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin rec

133 , documentation of ejection fraction, use of angiotensin-converting enzyme inhibitors/angiotensin rec

134 fills for beta-blockers, antiplatelet drugs, angiotensin-converting enzyme inhibitors/angiotensin-2 r

135 Use of antiplatelet agents and angiotensin-converting enzyme inhibitors/angiotensin-2 r

136 Angiotensin-converting enzyme inhibitors are associated

137 Because the pharmacologic effects of angiotensin-converting enzyme inhibitors are partly medi

138 reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-docume

139 eurohormonal activity (like beta-blockers or angiotensin-converting enzyme inhibitors) are considered

140 leroderma Clinical Trials Consortium confirm angiotensin-converting enzyme inhibitors as first-line t

141 edema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angio

142 ocked mice treated with ramipril for 7 days (angiotensin-converting enzyme inhibitors) before hemorrh

143 d and then subsequently filled prescriptions angiotensin-converting enzyme inhibitors, beta-blockers,

144 ar complications have also been treated with angiotensin-converting enzyme inhibitors, beta-blockers,

145 Suitable genetic proxies for angiotensin-converting enzyme inhibitors, beta-blockers,

146 that promoted antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure

147 angiotensin type 1 receptor blocker (ARB) or angiotensin-converting enzyme inhibitor can induce regre

148 Angiotensin-converting enzyme inhibitors can delay the p

149 , statins, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the

150 Combining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an

151 ptor blockers losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wou

152 wer of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase

153 ium oxide nanoparticles for the detection of angiotensin-converting enzyme inhibitor drug, captopril,

154 sin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg

155 ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and i

156 be prescribed lipid-lowering medication and angiotensin-converting enzyme inhibitors, especially if

157 should include calcium channel blockers and angiotensin-converting enzyme inhibitors for cardiovascu

158 lasses: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patien

159 ant prevented blood pressure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001

160 ume withdrawn was significantly lower in the angiotensin-converting enzyme inhibitor group than in th

161 lood lactate was significantly higher in the angiotensin-converting enzyme inhibitor group than in th

162 ation before the index date, those receiving angiotensin-converting enzyme inhibitors had a higher ri

163 In addition, the patients receiving angiotensin-converting enzyme inhibitors had a higher ri

164 Patients receiving beta-blockers or angiotensin-converting enzyme inhibitors had a higher ri

165 Many vasodilators including angiotensin-converting enzyme inhibitors have been evalu

166 Intracoronary angiotensin-converting enzyme inhibitors have been shown

167 giotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors (HR, 1.33; 95%

168 ant (HOE-140) immediately before anesthesia (angiotensin-converting enzyme inhibitors + icatibant), a

169 n, clopidogrel, beta-blocker, statin, and an angiotensin-converting enzyme inhibitor in patients with

170 nist-neprilysin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mort

171 s support the need to reevaluate the role of angiotensin-converting enzyme inhibitors in humans with

172 ith lower rates of sepsis and mortality than angiotensin-converting enzyme inhibitors in the patients

173 s a metabolite significantly associated with angiotensin-converting-enzyme inhibitors in our metabolo

174 ioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioede

175 II and III), acquired C1-INH deficiency, and angiotensin-converting enzyme inhibitor-induced angioede

176 The angiotensin converting enzyme inhibitor lisinopril and m

177 neficial ACE10 phenotype was reversed by the angiotensin-converting enzyme inhibitor (lisinopril) and

178 get (95/60 to 110/75 mm Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plu

179 erior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors (mean BP reduct

180 harmacologic therapy that includes either an angiotensin-converting enzyme inhibitor (moderate-qualit

181 nsin II type 1 receptor antagonists (n=6) or angiotensin-converting enzyme inhibitors (n=6) exhibited

182 patients more often received beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and

183 Moreover, an angiotensin-converting enzyme inhibitor normalized CXCR4

184 tes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin r

185 e, primary renal disease classification, and angiotensin converting enzyme inhibitor or angiotensin r

186 the renin-angiotensin system with either an angiotensin-converting enzyme inhibitor or a mineralocor

187 ent with a glomerular disease with either an angiotensin-converting enzyme inhibitor or an angiotensi

188 without diabetes who are currently taking an angiotensin-converting enzyme inhibitor or an angiotensi

189 -angiotensin-aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensi

190 ack patients and 18.2% of patients not on an angiotensin-converting enzyme inhibitor or angiotensin I

191 mol), who had been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin I

192 or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin I

193 oup had worse baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin r

194 d as prescription of beta-blocker and either angiotensin-converting enzyme inhibitor or angiotensin r

195 l or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin r

196 ssociation (NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin r

197 Most patients (84%) used an angiotensin-converting enzyme inhibitor or angiotensin r

198 ection fraction (93.4% versus 88.8%), use of angiotensin-converting enzyme inhibitor or angiotensin r

199 Angiotensin-converting enzyme inhibitor or angiotensin r

200 Of these patients, 40% received angiotensin-converting enzyme inhibitor or angiotensin r

201 ith symptomatic decreased LVEF, 67% received angiotensin-converting enzyme inhibitor or angiotensin r

202 th asymptomatic decreased LVEF, 31% received angiotensin-converting enzyme inhibitor or angiotensin r

203 (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin r

204 every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or beta-blocker

205 arm, patients on active therapy with either angiotensin-converting enzyme inhibitor or beta-blockers

206 estin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angio

207 Treatment with an angiotensin-converting enzyme inhibitor or mineralocorti

208 atory profile, and were less likely to be on angiotensin-converting enzyme inhibitors or aldosterone

209 clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin

210 ck patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin

211 elet P2Y12 receptor inhibitors, statins, and angiotensin-converting enzyme inhibitors or angiotensin

212 bing, indications, and contraindications for angiotensin-converting enzyme inhibitors or angiotensin

213 vention medications (statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin

214 giotensin-aldosterone system with the use of angiotensin-converting enzyme inhibitors or angiotensin

215 ary discharge diagnosis of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin

216 ose eligible at discharge were not receiving angiotensin-converting enzyme inhibitors or angiotensin

217 and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin

218 ves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin

219 0.017) but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin

220 beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin

221 e of antihypertensive medications other than angiotensin-converting enzyme inhibitors or angiotensin

222 Time-dependent effects of angiotensin-converting enzyme inhibitors or angiotensin

223 re, where use of beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin

224 95% CI, 0.75-0.99; P = 0.030) and trends for angiotensin-converting enzyme inhibitors or angiotensin

225 ng diuretics (95.9%), beta-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin

226 R, 4.17; [95% CI, 1.42-12.23]; P=0.009), and angiotensin-converting enzyme inhibitors or angiotensin

227 microalbuminuria followed by treatment with angiotensin-converting enzyme inhibitors or angiotensin

228 79) and the following discharge medications: angiotensin-converting enzyme inhibitors or angiotensin

229 h above 10 cm (p = 0.023), no treatment with angiotensin-converting enzyme inhibitors or angiotensin

230 Three randomized trials of angiotensin-converting enzyme inhibitors or angiotensin

231 ends in the uptake of key medical therapies (angiotensin-converting enzyme inhibitors or angiotensin

232 Angiotensin-converting enzyme inhibitors or angiotensin

233 At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin

234 e management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin

235 c obstructive pulmonary disease who received angiotensin-converting enzyme inhibitors or angiotensin

236 were receiving insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin

237 opathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin

238 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

239 All patients were treated with angiotensin-converting enzyme inhibitors or angiotensin-

240 giotensin system (RAS) blockade therapy with angiotensin-converting enzyme inhibitors or angiotensin-

241 Patients who were prescribed angiotensin-converting enzyme inhibitors or angiotensin-

242 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

243 th literacy and less likely to be prescribed angiotensin-converting enzyme inhibitors or beta-blocker

244 rpose of this study was to determine whether angiotensin-converting enzyme inhibitors or beta-blocker

245 between angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors or between diur

246 he renin- angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angi

247 on <40% (OR, 0.97 [95% CI, 0.69-1.35]), ACE (angiotensin-converting enzyme) inhibitor or angiotensin

248 um testing within 30 days of initiating ACE (angiotensin-converting enzyme) inhibitor or angiotensin

249 Results Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angio

250 vely low-cost heart failure medication (ACE [angiotensin-converting enzyme] inhibitor or angiotensin

251 300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensi

252 or blockers (OR = 0.70, 95% CI 0.54-0.92) or angiotensin-converting enzyme inhibitors (OR = 0.69, 95%

253 tion fraction (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiote

254 RAAS inhibition by enalapril (angiotensin-converting enzyme inhibitor) or losartan (an

255 n angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin

256 ary coverage for all statins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin

257 10 patients) for all statins, beta-blockers, angiotensin-converting-enzyme inhibitors, or angiotensin

258 Her medications include a beta-blocker, angiotensin-converting enzyme inhibitor, oral antidiabet

259 marital status, and baseline beta-blockers, angiotensin-converting enzyme inhibitors, oral anticoagu

260 g proportion of days covered for statins and angiotensin-converting enzyme inhibitors, patients were

261 As predicted, BALB/c mice pretreated with angiotensin-converting enzyme inhibitors potentiated IFN

262 Further, angiotensin-converting enzyme inhibitors potentiated TCT

263 blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic s

264 Angiotensin-converting enzyme inhibitors reduced mortali

265 s indicated that angiotensin II (Ang II) and angiotensin converting enzyme inhibitors regulated blood

266 Angiotensin-converting enzyme inhibitors (relative risk,

267 hereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.

268 in-II-antagonists, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, serotonin-spec

269 Angiotensin-converting enzyme inhibitor significantly de

270 ption of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitor, statins at disc

271 It is an angiotensin-converting enzyme inhibitor that operates vi

272 tments consider the use of beta-blockers and angiotensin-converting enzyme inhibitors that are sympto

273 treatment of avascular necrosis, and use of angiotensin-converting enzyme inhibitor therapy for micr

274 ia could identify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves

275 effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patie

276 hod to follow the immunomodulatory impact of angiotensin-converting enzyme inhibitor therapy on myelo

277 who derive significant clinical benefit from angiotensin-converting enzyme inhibitor therapy regardle

278 The ability of angiotensin-converting enzyme inhibitor therapy to prese

279 lled in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy) trial.

280 nts who derive greater clinical benefit from angiotensin-converting enzyme inhibitor therapy.

281 patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.

282 giotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Imp

283 tensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Imp

284 re use was high, ranging from 78% for use of angiotensin-converting enzyme inhibitors to 96% for use

285 in-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Im

286 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

287 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

288 in Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

289 eceptor blockade during hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.

290 This benefit could be of interest in angiotensin-converting enzyme inhibitor-treated patients

291 nuates the deleterious hemodynamic effect of angiotensin-converting enzyme inhibitor treatment in mic

292 resent findings support the possibility that angiotensin-converting enzyme inhibitor treatment might

293 with HF; however, retrospective analysis of angiotensin-converting enzyme inhibitor trials and prosp

294 sure, and no angiotensin II receptor blocker/angiotensin-converting enzyme inhibitor use were associa

295 rular status, birth weight, premature birth, angiotensin-converting enzyme inhibitor use, angiotensin

296 body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake w

297 associated with calcium channel blocker and angiotensin-converting enzyme inhibitor use.

298 n, other lipid-lowering agents, aspirin, and angiotensin-converting enzyme inhibitors was identified.

299 The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent

300 m, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that